Key Personnel Changes Nurix Inc recently made key personnel changes by appointing new leadership including a Chief Medical Officer and a Chief Technical Officer, signaling potential areas for collaboration or introducing new products to leverage their expertise.
Strategic Collaboration Extension Nurix Inc extended its strategic collaboration with Sanofi to develop novel targeted protein degraders of STAT6, highlighting a continued focus on innovation and potential joint market offerings for interested partners.
Public Offering Success Nurix Inc successfully went public recently, showcasing investor confidence and potential for partnerships or sales collaboration opportunities as the company expands and gains visibility.
Investment from Toussaintfinancial Toussaintfinancial's investment into Nurix Inc suggests financial backing and potential growth opportunities, opening avenues for partnership discussions or joint ventures within the industry.
Revenue and Funding Strength With solid revenue between $50M - $100M and funding of $175M, Nurix Inc showcases financial stability and growth potential, making them an attractive partner for collaborations, licensing agreements, or product acquisitions.
Nurix Therapeutics uses 8 technology products and services including GoTo Meeting, Akamai, Google Cloud, and more. Explore Nurix Therapeutics's tech stack below.
| Nurix Therapeutics Email Formats | Percentage |
| flast@nurixtx.com | 75% |
| last@nurixtx.com | 21% |
| first.last@nurixtx.com | 3% |
| fmiddlelast@nurixtx.com | 1% |
| flast@nurix-inc.com | 88% |
| last@nurix-inc.com | 8% |
| first@nurix-inc.com | 1% |
| fmiddlelast@nurix-inc.com | 1% |
| f.last@nurix-inc.com | 1% |
| lastf@nurix-inc.com | 1% |
| lfirst@nurix-inc.com | 0% |
Biotechnology ResearchCalifornia, United States201-500 Employees
Nurix Therapeutics discovers drugs that harness the body's natural process to control protein levels. Our drugs control ubiquitin E3 ligases, the key enzymes responsible for protein breakdown in human cells, as a unique therapeutic approach to treat a broad range of diseases. Our focus is on developing drugs to treat cancer including novel, small molecule immuno-oncology agents.
Company Overview
Media & News
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024.
Nurix Therapeutics's revenue is in the range of $50M$100M
Funding & FinancialsNurix Therapeutics has raised a total of $175M of funding over 8 rounds. Their latest funding round was raised on Apr 11, 2024.
Nurix Therapeutics's revenue is in the range of $50M$100M
Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.
1-888-653-2347 
support@leadiq.com